{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T12:45:12Z","timestamp":1792586712091,"version":"4.5.0"},"reference-count":0,"publisher":"The Journal of Food and Drug Analysis (JFDA), Food and Drug Administration, Taiwan (TFDA)","issue":"4","license":[{"start":{"date-parts":[[2024,12,14]],"date-time":"2024-12-14T00:00:00Z","timestamp":1734134400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Food and Drug Analysis"],"abstract":"<jats:p>This study was aimed to evaluate the cost-effectiveness of pembrolizumab with chemotherapy (pembrolizumabcombination therapy) and compare it with standard-of-care platinum-based chemotherapy (chemotherapy alone) as a \ufb01rst-line treatment for metastatic nonsquamous NSCLC from the perspective of Taiwan's third-party-payer public health-care system. We used a partitioned survival model with an estimated time horizon of 10 years. The partitionedsurvival model uses KaplaneMeier estimates of progression-free and overall survival from the KEYNOTE-189 clinicaltrial. The quality-adjusted life-year (QALY) values were based on utility values by progression status calculated from theKEYNOTE-189 trial. This study examined costs related to treatment regimens, disease management, second-line therapy,end-of-life care, and adverse event management. Cost and utility were discounted at 3% per year. Probabilistic anddeterministic sensitivity analyses were performed to test the robustness of the results. The willingness-to-pay threshold was set at 3 \u00d7 Taiwan's gross domestic product (GDP), equivalent to NT$2,788,290. In the base-case scenario, pem-brolizumab combination therapy resulted in an expected gain of 0.89 QALYs and an incremental cost of NT$2,201,203relative to chemotherapy alone. The ICER was NT$2,478,601\/QALY. In the analysis of the PD-L1 tumor proportion score (TPS) \u2265 50% subgroup, the patients who received pembrolizumab combination therapy gained 1.12 QALYs more than those who received chemotherapy alone, and the incremental cost was NT$2,522,528. Therefore, the ICER for this subset of patients was NT$2,258,358\/QALY. In conclusion, pembrolizumab combination therapy is a cost-effective option for\ufb01rst-line treatment of metastatic nonsquamous NSCLC. The relative cost-effectiveness of pembrolizumab combination therapy is greatest for patients with PD-L1 TPS \u226550%.<\/jats:p>","DOI":"10.38212\/2224-6614.3536","type":"journal-article","created":{"date-parts":[[2024,12,15]],"date-time":"2024-12-15T04:12:45Z","timestamp":1734235965000},"page":"568-576","source":"Crossref","is-referenced-by-count":1,"title":["Cost-effectiveness analysis of pembrolizumab with chemotherapy for metastatic nonsquamous non-small cell lung cancer in Taiwan"],"prefix":"10.38212","volume":"32","author":[{"given":"Wei-Ling","family":"Lee","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Taipei Chang Gung Memorial Hospital of the CGMF, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wan-Hsuan","family":"Chou","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, School of Pharmacy, Taipei Medical University, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Pin","family":"Chang","sequence":"additional","affiliation":[{"name":"School of Health Care Administration, College of Management, Taipei Medical University, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsung-Wei","family":"Chang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Yuanlin Christian Hospital, Changhua, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-Nan","family":"Kuo","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, School of Pharmacy, Taipei Medical University, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Chiao","family":"Chang","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, School of Pharmacy, Taipei Medical University, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"25385","published-online":{"date-parts":[[2024,12,14]]},"container-title":["Journal of Food and Drug Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jfda-online.com\/cgi\/viewcontent.cgi?article=3536&amp;context=journal","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T12:15:49Z","timestamp":1792584949000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jfda-online.com\/journal\/vol32\/iss4\/14"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,14]]},"references-count":0,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,12,14]]}},"URL":"https:\/\/doi.org\/10.38212\/2224-6614.3536","relation":{},"ISSN":["2224-6614"],"issn-type":[{"value":"2224-6614","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,14]]}}}